Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionOppenheimer Asset Management Inc.
Latest Disclosed Ownership14,313 shares
Latest Disclosed Value $ 1,885,594
Oppenheimer Asset Management Inc. reports 0.69% decrease in ownership of NBIX / Neurocrine Biosciences, Inc.

On April 23, 2026 - Oppenheimer Asset Management Inc. filed a 13F-HR form disclosing ownership of 14,313 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $1,885,594 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 2, 2026 disclosing 14,412 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of -0.69% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-23 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,313 -99 -0.69 1,886 -7.78 0.0054
2026-02-02 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,412 -968 -6.29 2,044 -5.33 0.0251
2025-11-06 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 15,380 -815 -5.03 2,159 6.09 0.0237
2025-07-31 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 16,195 2,202 15.74 2,036 31.54 0.0233
2025-04-23 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 13,993 49 0.35 1,548 -18.71 0.0192
2025-02-05 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 13,944 186 1.35 1,903 20.06 0.0231
2024-11-05 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 13,758 -1,388 -9.16 1,585 -23.98 0.0191
2024-08-08 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 15,146 1,725 12.85 2,085 12.64 0.0266
2024-05-07 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 13,421 -2,056 -13.28 1,851 -9.22 0.0271
2024-02-13 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 15,477 -452 -2.84 2,039 13.78 0.0284
2023-11-08 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 15,929 1,736 12.23 1,792 33.93 0.0275
2023-08-03 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,193 -12,027 -45.87 1,338 -49.57 0.0197
2023-05-10 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 26,220 -196 -0.74 2,654 -15.91 0.0409
2023-02-07 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 26,416 -3,833 -12.67 3,155 -1.81 0.0508
2022-11-14 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 30,249 -3,444 -10.22 3,213 -2.19 0.0567
2022-08-08 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 33,693 -920 -2.66 3,285 1.23 0.0550
2022-05-12 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 34,613 8,179 30.94 3,245 44.16 0.0461
2022-02-02 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 26,434 -2,362 -8.20 2,251 -18.50 0.0298
2021-11-12 2021-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 28,796 354 1.24 2,762 -0.22 0.0393
2021-08-03 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 28,442 674 2.43 2,768 2.48 0.0394
2021-05-17 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 27,768 2,532 10.03 2,701 11.66 0.0419
2021-02-11 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 25,236 -639 -2.47 2,419 -2.73 0.0404
2020-11-13 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 25,875 16,149 166.04 2,487 109.52 0.0483
2020-08-11 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 9,726 785 8.78 1,187 53.36 0.0245
2020-05-08 2020-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 8,941 1,383 18.30 774 -4.68 0.0190
2020-02-07 2019-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 7,558 82 1.10 812 20.47 0.0172
2019-10-31 2019-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 7,476 204 2.81 674 9.77 0.0150
2019-08-09 2019-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 7,272 -203 -2.72 614 -6.83 0.0136
2019-04-24 2019-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 7,475 700 10.33 659 36.16 0.0148
2019-01-30 2018-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 6,775 6,775 484 0.0120
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.